The FDA has confirmed the requirement for a confirmatory study involving the company Minerva.
3 reports, 1 independent
Updated Aug 7
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has confirmed the requirement for a confirmatory study involving the company Minerva.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- FDA accepted Milestone's response to the Complete Response Letter (CRL).
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Experimental therapies require approval from the FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireMinerva Neurosciences Provides Business Updates and Second Quarter Financial Results FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizoph